Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3118)
All Articles published online
|
Publishing Process of This Article
|
Jul 15, 2024 (publication date) through May 23, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yu PL, Yu Y, Li S, Mu BC, Nan MH, Pang M. Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety. World J Diabetes 2024; 15(7): 1518-1530 [PMID: 39099807 DOI: 10.4239/wjd.v15.i7.1518] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v15/i7/1518.htm |
| Number | Citing Articles |
| 1 |
Zhihang Su, Ziqi Luo, Di Wu, Wen Liu, Wangyang Li, Zheng Yin, Rui Xue, Liling Wu, Yuan Cheng, Qijun Wan. Causality between diabetes and membranous nephropathy: Mendelian randomization. Clinical and Experimental Nephrology 2025; 29(2): 227 doi: 10.1007/s10157-024-02566-8
|
| 2 |
Yinan Wang, Zi Wang, Xinning Guo, Zhengyu Tao, Chen Wu, Meng Jiang, Jun Pu. Empagliflozin attenuates DOX-induced cardiotoxicity by inhibiting RIPK1-mediated endoplasmic reticulum stress and autophagy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2025; 1871(6): 167898 doi: 10.1016/j.bbadis.2025.167898
|